AR087433A1 - Analogos de insulina n-glicosilados - Google Patents
Analogos de insulina n-glicosiladosInfo
- Publication number
- AR087433A1 AR087433A1 ARP120102824A ARP120102824A AR087433A1 AR 087433 A1 AR087433 A1 AR 087433A1 AR P120102824 A ARP120102824 A AR P120102824A AR P120102824 A ARP120102824 A AR P120102824A AR 087433 A1 AR087433 A1 AR 087433A1
- Authority
- AR
- Argentina
- Prior art keywords
- glycans
- group
- insulin analogs
- fucosylated
- glicosilated
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 abstract 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 3
- ZTOKCBJDEGPICW-UHFFFAOYSA-N Man3GlcNAc2 Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(CO)O1 ZTOKCBJDEGPICW-UHFFFAOYSA-N 0.000 abstract 3
- ZTOKCBJDEGPICW-GWPISINRSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](CO)O1 ZTOKCBJDEGPICW-GWPISINRSA-N 0.000 abstract 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen composiciones y formulaciones que comprenden análogos de insulina N-glicosilados. En realizaciones particulares, los análogos de insulina glicosilados se producen in vivo y comprenden uno o más de los N-glicanos N-enlazados seleccionados entre N-glicanos con alto contenido en manosa o fucosilado o no flicosilado híbrido, de paucimanosa o complejo. En otras realizaciones, el N-glicano que comprende el N-glicano con alto contenido en manosa o fucosilado o no fucosilado híbrido, de paucimanosa o complejo se une al análogo de insulina in vitro. Los ejemplos de N-glicanos incluyen pero sin limitación una molécula que tiene una estructura seleccionada entre los N-glicanos en el grupo que consiste en el Man(1-9)GlcNAc2; o seleccionada entre los N-glicanos en el grupo que consiste en GlcNAc(1-4)Man3GlcNAc2; o seleccionada entre los N-glicanos en el grupo que consiste en Gal(1-4)GlcNAc(1-4)Man3GlcNAc2; o seleccionada entre los N-glicanos en el grupo que consiste en NANA(1-4)Gal(1-4)GIcNAc(1-4)Man3GlcNAc2. Método para producir insulina. Uso para el tratamiento de diabetes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161521142P | 2011-08-08 | 2011-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087433A1 true AR087433A1 (es) | 2014-03-26 |
Family
ID=47668823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102824A AR087433A1 (es) | 2011-08-08 | 2012-08-02 | Analogos de insulina n-glicosilados |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20140235537A1 (es) |
| EP (1) | EP2744510A4 (es) |
| JP (1) | JP2014525922A (es) |
| KR (1) | KR20140057589A (es) |
| CN (1) | CN103889444A (es) |
| AR (1) | AR087433A1 (es) |
| AU (1) | AU2012294656A1 (es) |
| CA (1) | CA2843640A1 (es) |
| TW (1) | TW201311720A (es) |
| WO (1) | WO2013022721A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9328367B2 (en) * | 2011-10-28 | 2016-05-03 | Merck Sharp & Dohme Corp. | Engineered lower eukaryotic host strains for recombinant protein expression |
| ES2739280T3 (es) | 2013-07-04 | 2020-01-30 | Glykos Finland Oy | Células fúngicas filamentosas deficientes en O-manosiltransferasa y métodos de uso de las mismas |
| BR112016007176A2 (pt) * | 2013-10-04 | 2018-01-23 | Merck Sharp & Dohme | conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete |
| EP3172333B1 (en) | 2014-07-21 | 2020-05-13 | Glykos Finland Oy | Production of glycoproteins with mammalian-like n-glycans in filamentous fungi |
| KR102623965B1 (ko) | 2014-12-01 | 2024-01-11 | 암젠 인크 | 당단백질의 글리칸 함량 수준을 조작하는 방법 |
| US10822386B2 (en) * | 2014-12-24 | 2020-11-03 | Case Western Reserve University | Insulin analogues with enhanced stability and reduced mitogenicity |
| EP3249044A4 (en) | 2015-01-20 | 2018-11-07 | Suntory Holdings Limited | Method for preparing mogroside |
| WO2016144658A1 (en) * | 2015-03-10 | 2016-09-15 | Merck Sharp & Dohme Corp. | Process for preparing recombinant insulin using microfiltration |
| RU2736358C2 (ru) * | 2015-12-09 | 2020-11-16 | Общество С Ограниченной Ответственностью "Синбио" | Способ очистки полисиалированного инсулина человека |
| JP7170332B2 (ja) * | 2016-12-09 | 2022-11-14 | アクストン バイオサイエンシズ コーポレーション | インスリンとｆｃの融合物および使用方法 |
| GB2575756A (en) * | 2017-04-03 | 2020-01-22 | AmideBio LLC | Glucose-responsive insulin analogs and methods of use thereof |
| EP3668892A1 (en) | 2017-08-17 | 2020-06-24 | Novo Nordisk A/S | Novel acylated insulin analogues and uses thereof |
| WO2019154311A1 (zh) * | 2018-02-09 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种密码子优化的人胰岛素类似物前体基因和信号肽基因 |
| HUE065725T2 (hu) | 2018-06-29 | 2024-06-28 | Akston Biosciences Corp | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| HRP20231433T1 (hr) | 2019-12-19 | 2024-03-29 | Akston Biosciences Corporation | Inzulin-fc fuzijski proteini ultradugog djelovanja i načini uporabe |
| US11970722B2 (en) | 2019-12-20 | 2024-04-30 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| CA3166726A1 (en) * | 2020-01-07 | 2021-07-15 | Limmatech Biologics Ag | Glycoengineering using leishmania cells |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| HUE062716T2 (hu) | 2020-04-10 | 2023-11-28 | Akston Biosciences Corp | Antigénspecifikus immunterápia COVID-19 fúziós fehérjékhez és az alkalmazási eljárások |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CN111560379B (zh) * | 2020-05-26 | 2022-09-13 | 北京惠之衡生物科技有限公司 | 密码子优化的门冬胰岛素前体基因、重组载体、基因工程菌及其应用 |
| AU2020466305A1 (en) * | 2020-09-04 | 2023-05-18 | The Florey Institute Of Neuroscience And Mental Health | Derivatisation of peptides and proteins |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
| WO2024218743A1 (en) * | 2023-04-21 | 2024-10-24 | Glycoera Ag | Multi-functional molecules comprising glycans and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP940432B1 (en) * | 1994-08-05 | 2003-10-31 | Pliva Pharm & Chem Works | Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin |
| WO1999066054A2 (en) * | 1998-06-15 | 1999-12-23 | Genzyme Transgenics Corp. | Erythropoietin analog-human serum albumin fusion protein |
| EP1265630B1 (en) * | 2000-03-24 | 2006-06-07 | Genentech, Inc. | Use of insulin for the treatment of cartilagenous disorders |
| SG177002A1 (en) * | 2001-10-10 | 2012-01-30 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
| US8946148B2 (en) * | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| NZ594248A (en) * | 2009-01-28 | 2015-03-27 | Smartcells Inc | Conjugate based systems for controlled drug delivery |
-
2012
- 2012-08-02 AR ARP120102824A patent/AR087433A1/es not_active Application Discontinuation
- 2012-08-03 CN CN201280049481.4A patent/CN103889444A/zh active Pending
- 2012-08-03 US US14/237,369 patent/US20140235537A1/en not_active Abandoned
- 2012-08-03 WO PCT/US2012/049425 patent/WO2013022721A1/en not_active Ceased
- 2012-08-03 JP JP2014525071A patent/JP2014525922A/ja not_active Withdrawn
- 2012-08-03 KR KR1020147006029A patent/KR20140057589A/ko not_active Withdrawn
- 2012-08-03 AU AU2012294656A patent/AU2012294656A1/en not_active Abandoned
- 2012-08-03 EP EP12821921.9A patent/EP2744510A4/en not_active Withdrawn
- 2012-08-03 CA CA2843640A patent/CA2843640A1/en not_active Abandoned
- 2012-08-06 TW TW101128314A patent/TW201311720A/zh unknown
-
2016
- 2016-01-14 US US14/995,638 patent/US20160289290A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140235537A1 (en) | 2014-08-21 |
| KR20140057589A (ko) | 2014-05-13 |
| TW201311720A (zh) | 2013-03-16 |
| CA2843640A1 (en) | 2013-02-14 |
| US20160289290A1 (en) | 2016-10-06 |
| JP2014525922A (ja) | 2014-10-02 |
| EP2744510A1 (en) | 2014-06-25 |
| EP2744510A4 (en) | 2015-04-29 |
| AU2012294656A1 (en) | 2014-02-20 |
| WO2013022721A1 (en) | 2013-02-14 |
| CN103889444A (zh) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087433A1 (es) | Analogos de insulina n-glicosilados | |
| BR112014026755B8 (pt) | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer | |
| MY160680A (en) | Process for producing molecules containing specialized glycan structures | |
| BRPI0923702B8 (pt) | Composições inseticidas estáveis compreendendo spinosin e uma mistura esteroisomérica de sulfoxaflor, e seu método de produção | |
| BR112013009275A2 (pt) | glicoformas de anticorpo alfa de receptor anti-folato | |
| ECSP11010812A (es) | Complejo de mineral-aminoácido polisacárido | |
| MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
| BR112013032434A2 (pt) | restauração dentária, método para sua produção e vidro cerâmico | |
| BR112015013822A2 (pt) | método de vaso único para a síntese de cu-ssz-13, o composto obtido através do método e utilização do mesmo | |
| CL2008002873A1 (es) | Anticuerpo anti-glipican 3/gpc3; composicion que lo comprende; agente anti-canceroso que lo comprende; acido nucleico que codifica dicho anticuerpo; celula hospedera aislada que comprende dicho acido nucleico; metodo para la preparacion de dicho anticuerpo | |
| MY170912A (en) | Compositions comprising c6 oligosaccharides | |
| MY169317A (en) | Methods for converting lignocellulosic material to useful products | |
| WO2012168410A3 (en) | Methods for treating lignocellulosic material | |
| EA201590887A1 (ru) | Композиция | |
| WO2012020100A3 (en) | Compositions and methods for producing dendritic cells | |
| EA201491195A1 (ru) | Способ получения композиции, содержащей галактоолигосахариды | |
| WO2010007502A8 (en) | Platelet fraction deriving from placental blood | |
| EA201490024A1 (ru) | Наполненные силиконовые композиции, их получение и применение | |
| BR112014013648A2 (pt) | mancal deslizante | |
| GB201319839D0 (en) | Synthesis and use of glycoside derivatives of propofol | |
| BR112014000603A2 (pt) | método para produzir coloides de zircônia | |
| MX2010000979A (es) | Metodos y composiciones para tratar enfermedad autoinmune. | |
| BR112015020365A2 (pt) | fração bioativa derivada de fruta, composição, e método para isolar uma fração bioativa | |
| AU2010286532A8 (en) | Methods of treatment using anti-oxidized LDL antibodies | |
| CR20110251A (es) | Metodo para la obtencion de un extracto rico en taninos del acido elágico a partir de frutos que contiednen estos compuestos y extracto obtenido usando dicho metodo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |